Shilpa Medicare Q1 FY26: ₹321 Cr Sales, ₹47 Cr PAT, 59x P/E — Pharma Chemist Shop or Biotech Hedge Fund?
Date of Publishing -
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
1. At a Glance
Shilpa Medicare Ltd (SML) is the smallcap pharma that behaves like a biotech VC. Market cap = ₹7,548 Cr. CMP = ₹772. P/E = 58.7x — basically, more expensive than Cipla’s inhalers but with half the oxygen.
Quarterly sales ₹321 Cr (up 9.9%), PAT ₹47 Cr (up 234% — base effect ka magic). ROE just 4.2%, ROCE 7.8% — but promoters pledge 7.9% shares. Dividend yield: 0.06% — enough to buy one Disprin strip after taxes.
2. Introduction
Founded in 1987, Shilpa started as an API shop in Raichur and today dreams of becoming India’s Genentech (without the Silicon Valley coffee).
Oncology APIs are their bread-and-butter, supplying to USA, EU, Japan, and other regulators who send inspection letters more regularly than Diwali greetings. They also run contract development & manufacturing (CDMO), biosimilars, oral thin films, transdermal patches, biologics, and even trauma sprays like Dr. Clot (for battlefield bleeding — because why not?).
But financial reality check: sales CAGR 5-10%, profits yo-yoing like Sensex on budget day, debt ₹588 Cr, and working capital cycle at 350 days. Yes, 350. That’s longer than some Netflix series.
Question for you: Is Shilpa a pharma manufacturer or a science project incubator funded by investors’ patience?
3. Business Model – WTF Do They Even Do?
They’ve got more verticals than a South Indian thali:
